Remove Drug Pricing Remove Labelling Remove White Paper
article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. These actions allegedly led to the extension of Novartis’ patents.

article thumbnail

FDA removes safety programme for CAR-T therapies to boost uptake

Pharmaceutical Technology

The agency said that safety information can be adequately conveyed using drug product labelling. How will RFK Jr’s American dream for vaccines play out? This includes a boxed warning for the risks of CRS and neurological toxicities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Torrent Pharmaceuticals to acquire stake in JB Pharma for $3bn

Pharmaceutical Technology

of equity shares from JB employees at the same price per share as offered to KKR. of equity shares from JB employees at the same price per share as offered to KKR. How will RFK Jr’s American dream for vaccines play out?

article thumbnail

Vetter breaks ground on $285m US clinical manufacturing site

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out?

article thumbnail

Inflation, drug pricing and reimbursement constraints will challenge pharma sector

Pharmaceutical Technology

The survey results also indicated that drug pricing and reimbursement constraints will be the second biggest concern, hampering the industry’s growth, as indicated by 30% of the surveyed respondents. To adapt is the only way to thrive. Please check your email to download the Report.

article thumbnail

WHO accuses China of withholding Covid-19 genetic data

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out?

article thumbnail

AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancer

Pharmaceutical Technology

The European approval follows a similar decision made by the US Food and Drug Administration (FDA) in March 2025. Its European label covers a range of cancers, including lung, biliary tract, and liver, amongst others. How will RFK Jr’s American dream for vaccines play out?